Biodexa Pharmaceuticals PLC ADR (BDRX)
NASDAQ (CM) NASDAQ (CM) Primary 
Biodexa Pharmaceuticals Plc (BDRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
NEW YORK CITY, NY / ACCESSWIRE / October 29, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Biodexa Pharmaceuticals Plc ("Biodexa" or "the Company") (NASDAQ:BDRX). Investors who purchased Biodexa securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/BDRX.
ATTENTION Biodexa Pharmaceuticals Plc Investors: You May Have Been Affected by Fraud - Contact Levi & Korsinsky to Discuss Your Rights
NEW YORK, NY / ACCESSWIRE / October 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Biodexa Pharmaceuticals Plc ("Biodexa Pharmaceuticals Plc") (NASDAQ:BDRX) concerning possible violations of federal securities laws. On October 4, 2024, Biodexa reported updated data on progression-free and overall survival from a Phase 1 study of its drug MX110 in the treatment of recurrent glioblastoma.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biodexa Pharmaceuticals Plc - BDRX
NEW YORK, NY / ACCESSWIRE / October 27, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Biodexa Pharmaceuticals Plc ("Biodexa" or the "Company") (NASDAQ:BDRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biodexa Pharmaceuticals Plc - BDRX
NEW YORK, NY / ACCESSWIRE / October 27, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Biodexa Pharmaceuticals Plc ("Biodexa" or the "Company") (NASDAQ:BDRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Biodexa Pharmaceuticals Plc (BDRX) And Encourages Stockholders to Connect
NEW YORK CITY, NY / ACCESSWIRE / October 27, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Biodexa Pharmaceuticals Plc ("Biodexa" or "the Company") (NASDAQ:BDRX). Investors who purchased Biodexa securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/BDRX.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biodexa Pharmaceuticals Plc - BDRX
NEW YORK, NY / ACCESSWIRE / October 23, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Biodexa Pharmaceuticals Plc ("Biodexa" or the "Company") (NASDAQ:BDRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Biodexa Pharmaceuticals Plc INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Biodexa Pharmaceuticals Plc (BDRX)
NEW YORK, NY / ACCESSWIRE / October 23, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Biodexa Pharmaceuticals Plc ("Biodexa Pharmaceuticals Plc") (NASDAQ:BDRX) concerning possible violations of federal securities laws. On October 4, 2024, Biodexa reported updated data on progression-free and overall survival from a Phase 1 study of its drug MX110 in the treatment of recurrent glioblastoma.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Biodexa Pharmaceuticals Plc (BDRX) And Encourages Shareholders to Reach Out
NEW YORK CITY, NY / ACCESSWIRE / October 23, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Biodexa Pharmaceuticals Plc ("Biodexa" or "the Company") (NASDAQ:BDRX). Investors who purchased Biodexa securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/BDRX.
Biodexa Pharmaceuticals Plc (BDRX) Shareholders May Have Been Affected by Fraud - Levi & Korsinsky Investigates
NEW YORK, NY / ACCESSWIRE / October 22, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Biodexa Pharmaceuticals Plc ("Biodexa Pharmaceuticals Plc") (NASDAQ:BDRX) concerning possible violations of federal securities laws. On October 4, 2024, Biodexa reported updated data on progression-free and overall survival from a Phase 1 study of its drug MX110 in the treatment of recurrent glioblastoma.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Biodexa Pharmaceuticals Plc (BDRX) and Encourages Investors to Learn More About the Investigation
NEW YORK CITY, NY / ACCESSWIRE / October 22, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Biodexa Pharmaceuticals Plc ("Biodexa" or "the Company") (NASDAQ:BDRX). Investors who purchased Biodexa securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/BDRX.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biodexa Pharmaceuticals Plc - BDRX
NEW YORK, NY / ACCESSWIRE / October 21, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Biodexa Pharmaceuticals Plc ("Biodexa" or the "Company") (NASDAQ:BDRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Biodexa Pharmaceuticals Plc Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - BDRX
NEW YORK, NY / ACCESSWIRE / October 21, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Biodexa Pharmaceuticals Plc ("Biodexa Pharmaceuticals Plc") (NASDAQ:BDRX) concerning possible violations of federal securities laws. On October 4, 2024, Biodexa reported updated data on progression-free and overall survival from a Phase 1 study of its drug MX110 in the treatment of recurrent glioblastoma.
